Author: Customer Service

Hangzhou, China, Dec. 24, 2025 (GLOBE NEWSWIRE) — WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, today announced that it will effect a reverse stock split of its ordinary shares on a 1-for-100 basis (the “Reverse Stock Split”). The Company’s Class A ordinary shares will begin trading on a post-split basis when the market opens on December 29, 2025. The Company’s Class A ordinary shares will continue to trade on the Nasdaq Capital Market under the symbol “WOK,” with a new CUSIP number G9767H125. The Reverse Stock Split has been approved by the Company’s shareholders and the Company’s board of directors, and is being effectuated primarily to maintain...

TUCSON, Ariz., Dec. 24, 2025 (GLOBE NEWSWIRE) — Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that it has entered into a definitive agreement for a private placement financing of up to $50.0 million aggregate principal amount of senior secured notes due 2028 together with warrants to purchase common stock of the Company. WestPark Capital Inc. served as Sole Placement Agent. The Company expects to issue an initial $15.0 million principal amount of notes at closing with the option to fund up to an additional $35.0 million principal amount in one or more tranches subject to certain conditions. The notes will be senior secured obligations of the Company. The...

VANCOUVER, British Columbia, Dec. 24, 2025 (GLOBE NEWSWIRE) — Westhaven Gold Corp. (TSX-V: WHN) (“Westhaven” or the “Company”) announces that, pursuant to the terms of the Company’s Stock Option Plan, Westhaven has granted 400,000 incentive stock options to an Officer of the Company. The options are exercisable at CDN$0.25 per share and can be exercised until December 23, 2030.  Following this grant of stock options there are 16,805,000 stock options outstanding, representing 6.9% of the Company’s issued and outstanding common shares. Investor Relations Agreement with Peterson Capital The Company is also announcing, effective January 1, 2026, it has entered into a consulting agreement (the “Agreement”) with Grignan Holdings Ltd. dba Peterson Capital (“Peterson Capital”) to provide investor relations services in compliance...

Initial Orders Validate Demand and Support Factory Utilization Strategy KISSIMMEE, Fla., Dec. 24, 2025 (GLOBE NEWSWIRE) — ECD Automotive Design, Inc. (“ECD” or the “Company”) (NASDAQ: ECDA), the world’s largest Land Rover and Jaguar restoration company known for its custom luxury builds, including bespoke Defenders, Range Rovers, Jaguar E-Types, Ford Mustangs, and Toyota FJs, today provided an update on the third-party build agreement announced earlier this month, highlighting early commercial traction and progress to increase factory utilization and improve fixed-cost absorption. Since announcing the agreement with a regional 4×4 restoration client, ECD has received its first six orders. The Company expects to execute these builds at its Kissimmee, Florida facility across the first and second quarters of 2026. ECD has allocated...

Tel Aviv, Israel, Dec. 24, 2025 (GLOBE NEWSWIRE) — Jeffs’ Brands Ltd. (Nasdaq: JFBR) (“Jeffs’ Brands”),  a data-driven e-commerce company strategically pivoting into homeland security, today provided additional information regarding Scanary Ltd. (“Scanary”), an Israeli deep-tech startup’s groundbreaking AI-powered radar system that promises to redefine concealed threat detection without disrupting the flow of people. In an era of emerging security threats-from mass shootings to terrorist attacks in crowded public spaces—traditional security screening methods are increasingly inadequate. Long lines at metal detectors and X-ray machines create bottlenecks, frustrate crowds, and leave vulnerabilities in open areas where threats can enter undetected. Enter Scanary Ltd. (“Scanary”), an Israeli deep-tech startup’s...

Vancouver, Canada, Dec. 24, 2025 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today reflected on a year of significant momentum and progress in advancing its lead candidate, CMND-100, for the treatment of Alcohol Use Disorder (AUD). Throughout 2025, Clearmind achieved critical milestones in its FDA-approved Phase I/IIa clinical trial for CMND-100, a proprietary non-hallucinogenic MEAI-based oral compound designed to address AUD—a condition affecting millions worldwide with limited effective treatment options. Key 2025 highlights include: Clinical Trial Progress: Advanced the multinational Phase I/IIa...

BURLINGTON, Mass., Dec. 24, 2025 (GLOBE NEWSWIRE) — Cerence Inc. (NASDAQ: CRNC) (“Cerence AI”), a global leader pioneering conversational AI-powered user experiences, today announced that, in light of its current cash position and outlook for future cash generation, the Company entered into privately negotiated transactions with certain holders of its 1.50% Convertible Senior Notes Due 2028 (the “Notes”), pursuant to which the Company agreed to repurchase $30 million aggregate principal amount of the Notes from such holders at a cash repurchase price equal to 92% of their principal amount, together with the accrued and unpaid interest thereon to (but not including) the settlement date. The repurchase of the Notes at a price below par represents a strategic decision by the Company to utilize its cash reserves efficiently. The transaction...